CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- SC 13D/A Stake Beneficial Ownership Report
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market buy 10% owner bought 560,000 shares at an average $1.40 ($783,840)
- 3 Insider Initial Statement of Ownership
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Exit or restructuring costs · Executive or director change · Other events
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market sale 10% owner sold 694,551 shares at an average $1.08 ($751,256)
- 424B5 Offering Prospectus
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market buy Director bought 151,472 shares at an average $1.45 ($219,667)
- 4 Open-market buy Director bought 45,926 shares at an average $1.19 ($54,673)
- 4 Open-market buy Director bought 31,826 shares at an average $1.23 ($39,246)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Grant or award SVP, CMO acquired 34,100 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 131,400 shares (grant or award)
Page 33 of 40 · 798 filings